Closed · RFA-CA-10-003 · CFDA 93.393;93.394;93.395;93.396 · Discretionary

Application and Early Stage Development of Emerging Technologies in Cancer Research (R21)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $200K
Award range
Closed
Status
September 30, 2010
Close date
-
Expected awards

The verdict

Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) is a closed discretionary listing from National Institutes of Health that offered Up to $200,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $200K
award range
Closed
application status
93.393;93.394;93.395;93.396
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Application and Early Stage Development of Em… is closed (last close September 30, 2010). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed September 30, 2010

Posted Oct 26 Closes Sep 30

Est. Total Funding

$2,250,000

Instrument

Grant

Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications that propose exploratory research projects on the initial application of emerging analytical technologies as laboratory or clinical tools. An emerging technology is defined as one that has passed the initial developmental stage, but has not yet been evaluated within the context of its intended use. Projects proposed in response to this FOA should have the potential to produce a major impact in a broad area of cancer-relevant research. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R21 applications that have high potential impact and allows for an element of technical risk; preliminary data are not required. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-004, that solicits applications under the NIH Application R33 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $2,250,000 to this FOA in fiscal year 2010 to fund up to 7 applications in response to this FOA. Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.

Market-open applicant set · includes for-profit door

The eligibility set for Application and Early Stage Development of Em… includes a for-profit door among 8 printed types (State governments; Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); +4 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). Only 98 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).

Code 00
State governments
Code 06
Public / state-controlled institutions of higher education
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Application and Early Stage Development of Em… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.393;93.394;93.395;93.396 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants